• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可切除胆管癌的处理方法。

Approach to Resectable Biliary Cancers.

机构信息

Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 S.W. Sam Jackson, Portland, OR, 97239, USA.

出版信息

Curr Treat Options Oncol. 2021 Sep 15;22(11):97. doi: 10.1007/s11864-021-00896-3.

DOI:10.1007/s11864-021-00896-3
PMID:34524554
Abstract

Biliary malignancies, although rare, can be some of the most challenging to manage surgically. Intrahepatic cholangiocarcinomas are resectable if there is no evidence of metastatic disease. These tumors are managed with anatomic resection and portal lymphadenectomy when centrally located or multiple in a single lobe. Non-anatomic resection can be performed for solitary peripheral tumors with minimally invasive techniques. It is not our practice to routinely employ neoadjuvant chemotherapy prior to resection of these tumors. Hepatic arterial infusion chemotherapy is utilized at our institution in highly selected patients in the context of an ongoing clinical trial for unresectable tumors. Hilar cholangiocarcinomas, when resectable (i.e., ipsilateral arterial involvement or lack of vascular involvement), are managed with right or left (extended) hepatectomy, caudate resection, and portal lymphadenectomy. Distal cholangiocarcinomas are managed with pancreaticoduodenectomy. Neoadjuvant chemotherapy is not routinely used in our treatment algorithm of extrahepatic cholangiocarcinomas. Nodal involvement and positive margin (R1) resection necessitates adjuvant chemotherapy. Finally, gallbladder carcinoma is managed with radical cholecystectomy, anatomic segment IVb/V resection, and portal lymphadenectomy. Adjuvant chemotherapy is employed routinely amongst patients with T2 or higher tumors and those with positive lymph nodes.

摘要

胆道恶性肿瘤虽然罕见,但在手术治疗方面可能极具挑战性。如果没有转移性疾病的证据,肝内胆管癌是可切除的。这些肿瘤位于中央或单个叶内多发时,采用解剖性切除术和门静脉淋巴结清扫术治疗。对于单发的外周肿瘤,可以采用微创技术进行非解剖性切除术。我们的实践中不常规在切除这些肿瘤之前使用新辅助化疗。在我们的机构中,对于无法切除的肿瘤,在一项正在进行的临床试验背景下,将肝动脉灌注化疗用于高度选择的患者。可切除的肝门部胆管癌(即同侧动脉受累或无血管受累)采用右或左(扩大)肝切除术、尾状叶切除术和门静脉淋巴结清扫术治疗。远端胆管癌采用胰十二指肠切除术治疗。我们的治疗方案中不常规使用新辅助化疗来治疗肝外胆管癌。淋巴结受累和阳性切缘(R1)切除需要辅助化疗。最后,胆囊癌采用根治性胆囊切除术、解剖性 IVb/V 段切除术和门静脉淋巴结清扫术治疗。对于 T2 或更高肿瘤和淋巴结阳性的患者,常规采用辅助化疗。

相似文献

1
Approach to Resectable Biliary Cancers.可切除胆管癌的处理方法。
Curr Treat Options Oncol. 2021 Sep 15;22(11):97. doi: 10.1007/s11864-021-00896-3.
2
Multimodality Management of Localized Biliary Cancer.局部胆癌的多模态管理。
Curr Treat Options Oncol. 2019 May 29;20(7):58. doi: 10.1007/s11864-019-0655-0.
3
Surgical Therapy of Cholangiocarcinoma.胆管癌的外科治疗
Visc Med. 2016 Dec;32(6):422-426. doi: 10.1159/000452921. Epub 2016 Nov 30.
4
S4a + S5 with caudate lobe (S1) resection using the Taj Mahal liver parenchymal resection for carcinoma of the biliary tract.采用泰姬陵肝实质切除术对伴有尾状叶(S1)的S4a + S5进行胆管癌切除术。
J Gastrointest Surg. 1999 Jul-Aug;3(4):369-73. doi: 10.1016/s1091-255x(99)80052-3.
5
Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment.胆道和壶腹癌管理指南:手术治疗
J Hepatobiliary Pancreat Surg. 2008;15(1):41-54. doi: 10.1007/s00534-007-1279-5. Epub 2008 Feb 16.
6
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.门静脉切除对肝门部胆管癌预后的影响:305 例多机构分析。
Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.
7
Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States.未能为美国淋巴结阳性胆道癌患者提供多模式治疗会导致其治疗效果欠佳。
Surg Oncol. 2020 Sep;34:298-303. doi: 10.1016/j.suronc.2020.06.004. Epub 2020 Jun 30.
8
Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up.两百四十例连续的在扩大肝切除术前进行的门静脉栓塞治疗胆管癌:手术结果及长期随访
Ann Surg. 2006 Mar;243(3):364-72. doi: 10.1097/01.sla.0000201482.11876.14.
9
Surgical management of cholangiocarcinoma.胆管癌的外科治疗
Semin Liver Dis. 2004 May;24(2):189-99. doi: 10.1055/s-2004-828895.
10
[Radical surgery for hilar cholangiocarcinoma (Klatskin tumor)].肝门部胆管癌(克氏瘤)的根治性手术
Cir Esp. 2007 Jul;82(1):11-5. doi: 10.1016/s0009-739x(07)71654-8.

引用本文的文献

1
Standardized reporting of extrahepatic cholangiocarcinoma.肝外胆管癌的标准化报告
Abdom Radiol (NY). 2025 Sep 13. doi: 10.1007/s00261-025-05196-0.
2
Hepatopancreatoduodenectomy for Extrahepatic Cholangiocarcinoma: A Series of 100 Consecutive Cases from an Expert Center in Japan.肝胰十二指肠切除术治疗肝外胆管癌:来自日本一个专家中心的100例连续病例系列
Ann Surg Oncol. 2025 May 21. doi: 10.1245/s10434-025-17515-2.
3
A prognostic model and novel risk classification system for radical gallbladder cancer surgery: A population-based study and external validation.

本文引用的文献

1
Prognostic Impact of Paraaortic Lymph Node Metastasis in Extrahepatic Cholangiocarcinoma.肝外胆管癌腹主动脉旁淋巴结转移的预后影响。
World J Surg. 2021 Feb;45(2):581-589. doi: 10.1007/s00268-020-05834-2. Epub 2020 Oct 20.
2
Safety and Oncological Benefit of Hepatopancreatoduodenectomy for Advanced Extrahepatic Cholangiocarcinoma with Horizontal Tumor Spread: Shinshu University Experience.肝胰十二指肠切除术治疗伴有水平肿瘤扩散的晚期肝外胆管癌的安全性和肿瘤学获益:信州大学经验
Ann Surg Oncol. 2021 Apr;28(4):2012-2025. doi: 10.1245/s10434-020-09209-8. Epub 2020 Oct 12.
3
Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study.
根治性胆囊癌手术的预后模型和新型风险分类系统:一项基于人群的研究及外部验证
Heliyon. 2024 Aug 2;10(15):e35551. doi: 10.1016/j.heliyon.2024.e35551. eCollection 2024 Aug 15.
4
New trends in diagnosis and management of gallbladder carcinoma.胆囊癌诊断与治疗的新趋势
World J Gastrointest Oncol. 2024 Jan 15;16(1):13-29. doi: 10.4251/wjgo.v16.i1.13.
5
Oncologic safety of robotic extended cholecystectomy for gallbladder cancer.机器人辅助扩大胆囊切除术治疗胆囊癌的肿瘤学安全性
Surg Endosc. 2023 Dec;37(12):9089-9097. doi: 10.1007/s00464-023-10463-6. Epub 2023 Oct 5.
6
Biliary-enteric reconstruction in laparoscopic radical resection of hilar cholangiocarcinoma: a single-center retrospective cohort study.腹腔镜肝门部胆管癌根治术中胆肠吻合术:单中心回顾性队列研究。
BMC Cancer. 2023 May 18;23(1):456. doi: 10.1186/s12885-023-10942-y.
7
Prognostic influence for hilar cholangiocarcinoma and comparisons of prognostic values of Mayo staging and TNM staging systems.肝门部胆管癌的预后影响及 Mayo 分期和 TNM 分期系统预后价值的比较。
Medicine (Baltimore). 2022 Dec 9;101(49):e32250. doi: 10.1097/MD.0000000000032250.
8
Progress and Current Limitations of Materials for Artificial Bile Duct Engineering.人工胆管工程材料的研究进展与当前局限
Materials (Basel). 2021 Dec 6;14(23):7468. doi: 10.3390/ma14237468.
复发性肝内胆管癌的重复切除术:一项德国多中心回顾性研究。
Liver Int. 2021 Jan;41(1):180-191. doi: 10.1111/liv.14682.
4
ASO Author Reflection: Trends and Impact of Adjuvant Chemotherapy in Resected Gallbladder Cancer: Going Beyond Trial Data.ASO作者反思:辅助化疗在胆囊癌切除术后的趋势及影响:超越试验数据
Ann Surg Oncol. 2021 Mar;28(3):1481-1482. doi: 10.1245/s10434-020-08979-5. Epub 2020 Aug 5.
5
Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments.当前肝内胆管癌的治疗策略:从手术切除到姑息治疗。
Radiol Oncol. 2020 Jul 29;54(3):263-271. doi: 10.2478/raon-2020-0045.
6
A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).一项多机构试验(东京胆道癌研究组:TOSBIC01)中辅助替吉奥治疗可切除胆道癌一年的前瞻性可行性研究。
BMC Cancer. 2020 Jul 23;20(1):688. doi: 10.1186/s12885-020-07185-6.
7
Prognostic impact of tumor location in resected gallbladder cancer: A national cohort analysis.切除胆囊癌肿瘤位置对预后的影响:全国队列分析。
J Surg Oncol. 2020 Nov;122(6):1084-1093. doi: 10.1002/jso.26107. Epub 2020 Jul 11.
8
Laparoscopic liver resection versus open liver resection for intrahepatic cholangiocarcinoma: 3-year outcomes of a cohort study with propensity score matching.腹腔镜肝切除术与开腹肝切除术治疗肝内胆管细胞癌:倾向评分匹配队列研究的 3 年结果。
Surg Oncol. 2020 Jun;33:63-69. doi: 10.1016/j.suronc.2020.01.001. Epub 2020 Jan 14.
9
Proposal of the optimal numbers of examined and positive lymph nodes to the 8th edition of American Joint Committee on Cancer (AJCC) staging for 758 patients with distal cholangiocarcinoma.建议对 758 例远端胆管癌患者的第 8 版美国癌症联合委员会(AJCC)分期进行检查和阳性淋巴结的最佳数量。
PLoS One. 2020 Jun 16;15(6):e0234464. doi: 10.1371/journal.pone.0234464. eCollection 2020.
10
Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma.经放射性栓塞或化疗降期治疗初始不可切除的肝内胆管细胞癌。
Ann Surg Oncol. 2020 Oct;27(10):3729-3737. doi: 10.1245/s10434-020-08486-7. Epub 2020 May 29.